(Q48606434)

13 February 2018

title

Rebiopsy during disease progression in patients treated by TKI for oncogene-addicted NSCLC. (English)

1 reference

13 February 2018

author

Gilbert R Ferretti

2

1 reference

13 February 2018

Clarisse Audigier-Valette

4

object named as

Clarisse Audigier-Valette

1 reference

13 February 2018

Jacques Cadranel

3

object named as

Jacques Cadranel

1 reference

13 February 2018

author name string

Cecile Bosc

1

1 reference

13 February 2018

Benjamin Besse

5

1 reference

13 February 2018

Fabrice Barlesi

6

1 reference

13 February 2018

Chantal Decroisette

7

1 reference

13 February 2018

Sylvie Lantuejoul

8

1 reference

13 February 2018

François Arbib

9

1 reference

13 February 2018

Denis Moro-Sibilot

10

1 reference

13 February 2018

publication date

15 August 2014

1 reference

13 February 2018

published in

Targeted oncology

1 reference

13 February 2018

volume

10

1 reference

13 February 2018

issue

2

1 reference

13 February 2018

page(s)

247-253

1 reference

13 February 2018

https://scigraph.springernature.com/pub.10.1007/s11523-014-0332-y

exact match

0 references

cites work

Lung cancer occurrence in never-smokers: an analysis of 13 cohorts and 22 cancer registry studies

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0332-Y

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0332-Y

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0332-Y

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0332-Y

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0332-Y

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0332-Y

Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0332-Y

Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0332-Y

Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0332-Y

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0332-Y

Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0332-Y

Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0332-Y

Use of research biopsies in clinical trials: are risks and benefits adequately discussed?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0332-Y

Toward improved understanding of the ethical and clinical issues surrounding mandatory research biopsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0332-Y

The tissue is the issue: personalized medicine for non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0332-Y

Acquired resistance to targeted therapies in advanced non-small cell lung cancer: new strategies and new agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0332-Y

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0332-Y

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0332-Y

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0332-Y

Response to crizotinib rechallenge after initial progression and intervening chemotherapy in ALK lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0332-Y

Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0332-Y

Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0332-Y

Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0332-Y

Analysis of the effect of various decalcification agents on the quantity and quality of nucleic acid (DNA and RNA) recovered from bone biopsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0332-Y

Detection of mutations in EGFR in circulating lung-cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0332-Y

Biomarkers are here to stay for clinical research and standard care

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25119973

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Clinical significance of circulating tumor cells and free DNA in non-small cell lung cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25119973

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

EGFR mutations in circulating tumour DNA

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25119973

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S11523-014-0332-Y

1 reference

13 February 2018

1 reference

13 February 2018